The EU's oversight of takeovers and acquisitions is undergoing its biggest revolution since the bloc's merger review was introduced in 1989. A plethora of new initiatives at the national and EU level will see certain dealmakers — Big Tech, Big Pharma and Chinese buyers — navigating a maze of checks and approvals.